UNITED STATES SECURITIES AND EXCHANGE COMMISSION January 9, 2017

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Ultragenyx Pharmaceutical Inc.

File No. 001-36276 - CF#34124

Ultragenyx Pharmaceutical Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed August 9, 2016, as amended on December 12, 2016.

Based on representations by Ultragenyx Pharmaceutical Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.1 through June 6, 2026 Exhibit 10.2 through June 6, 2026

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary